ID: ALA5197737

Max Phase: Preclinical

Molecular Formula: C18H28N8O

Molecular Weight: 372.48

Associated Items:

Representations

Canonical SMILES:  COc1ccccc1N1CCN(CCCCNc2nc(N)nc(N)n2)CC1

Standard InChI:  InChI=1S/C18H28N8O/c1-27-15-7-3-2-6-14(15)26-12-10-25(11-13-26)9-5-4-8-21-18-23-16(19)22-17(20)24-18/h2-3,6-7H,4-5,8-13H2,1H3,(H5,19,20,21,22,23,24)

Standard InChI Key:  IBPKFKZAYBVENB-UHFFFAOYSA-N

Associated Targets(Human)

Serotonin 1a (5-HT1a) receptor 14969 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Serotonin 2a (5-HT2a) receptor 14758 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Serotonin 6 (5-HT6) receptor 9749 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Serotonin 7 (5-HT7) receptor 5576 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Dopamine D2 receptor 23596 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Topical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Properties

Molecular Weight: 372.48Molecular Weight (Monoisotopic): 372.2386AlogP: 1.06#Rotatable Bonds: 8
Polar Surface Area: 118.45Molecular Species: BASEHBA: 9HBD: 3
#RO5 Violations: 0HBA (Lipinski): 9HBD (Lipinski): 5#RO5 Violations (Lipinski): 0
CX Acidic pKa: CX Basic pKa: 9.42CX LogP: 1.88CX LogD: -0.50
Aromatic Rings: 2Heavy Atoms: 27QED Weighted: 0.58Np Likeness Score: -1.49

References

1. Kułaga D, Drabczyk AK, Satała G, Latacz G, Rózga K, Plażuk D, Jaśkowska J..  (2022)  Design and synthesis of new potent 5-HT7 receptor ligands as a candidate for the treatment of central nervous system diseases.,  227  [PMID:34710746] [10.1016/j.ejmech.2021.113931]

Source